TMB reported robust Q1FY27 performance with Net Profit rising 34.97% YoY to ₹412 Cr. Strategy focuses on 'RAM' advances and maintaining industry-leading capital adequacy at 32.33%.
CIE India reported Q2 CY26 consolidated sales of INR 25.4 billion, up 11% YoY. Strategy focuses on disciplined growth and maintaining healthy margins despite inflation.
Mold-Tek Packaging reported strong Q1 FY27 results with 24.9% revenue growth and 14.2% PAT growth, driven by IML adoption and pharma segment expansion.
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
SMC Global Securities reported Q1 FY27 consolidated revenue of INR 515.1 Cr (+21.2% Y-o-Y) and PAT of INR 36.7 Cr (+22.3% Y-o-Y). Strategy focuses on AI technology investments and insurance distribution.
Regency Fincorp Q1 FY27 results show 86% YoY income growth, reaching ₹17.4 Cr. The company is pivoting toward secured MSME lending and digital salary advances (Cash My Salary).
SAIL reported Q1 FY27 Revenue of Rs. 26,010 crore with a PAT of Rs. 1,636 crore. Focus remains on operational efficiency with EBITDA margin improving to 16.7%.
Bhagyanagar India Limited reports Q1FY27 revenue of ₹705.08 Cr with 45.2% YoY growth. Company is transitioning towards high-margin value-added copper products and executing a strategic demerger of its copper business.
Tata Motors Limited delivered structural EBITDA expansion to 13.2% in FY26. Management is pivoting to a pure-play CV entity but flags severe commodity and geopolitical headwinds for FY27.
Redington is pivoting from a hardware-centric transactional distributor to a high-margin software and services orchestrator. Management targets doubling the Software Services Group (SSG) revenue over the next three years.
Canara Bank reported Q1 FY27 Net Profit of ₹4,856 Cr (up 2.19% YoY) and Global Gross Business of ₹29,05,066 Cr (up 14.37% YoY). Strategy focuses on RAM segment credit growth.
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.